The North America blood collection tubes for liquid biopsy market was valued at US$ 44,385.94 million in 2023 and is expected to reach US$ 1,68,467.30 million by 2031; it is estimated to register a CAGR of 18.1% from 2023 to 2031.
Health systems across the world are witnessing an exponential increase in the prevalence of cancer. The World Health Organization (WHO) ranks cancer as the second-leading cause of mortality worldwide. According to data published by the World Cancer Research Fund International, ~20 million new cases of cancer were registered in 2022 globally. Moreover, as per the data published by the World Health Organization (WHO), nearly 10 million deaths were caused by cancer in 2020 across the world. The National Center for Health Statistics data estimates that the diagnosis of new cancer cases in the US is likely to reach 2 million in 2024. In addition, approximately 0.61 million people were anticipated to die in 2024 in the US due to cancer.
Early prognosis, tumor heterogeneity detection, reduced cost, and patient comfort are a few of the advantages of liquid biopsy over other cancer diagnostics approaches. Thus, the preference for liquid biopsy, allowing for quick treatment and enhancing cancer patients' survival rates, is increasing with the rise in cancer prevalence during the projection period. Blood collection tubes that are used in liquid biopsy play an instrumental role in the early and precise cancer detection strategies of various organizations. Thus, the increasing prevalence of cancer is contributing significantly to the growth of the North America blood collection tubes for liquid biopsy market.
The North America blood collection tubes for liquid biopsy market is segmented into the US, Canada, and Mexico. The market for liquid biopsy procedures is growing rapidly in the US with the surging prevalence of cancer, high spending on the development of innovative diagnostics solutions, and the presence of significant market players in the country. The National Cancer Institute estimates that ~2 million new cases of cancer would be registered in the US in 2024, and ~611,720 people are expected to die due to cancer. As per the same source, ~440.5 per 100,000 people are nearly diagnosed with cancer every year. Tissue biopsies are highly invasive techniques employed for lung cancer diagnosis. As the insufficiency of samples may result in nonreliable results in this type of biopsy, researchers focus on the development of liquid biopsy techniques for lung cancer diagnoses.
Strategic insights for the North America Blood Collection Tubes for Liquid Biopsy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the North America Blood Collection Tubes for Liquid Biopsy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.North America Blood Collection Tubes for Liquid Biopsy Strategic Insights
North America Blood Collection Tubes for Liquid Biopsy Report Scope
Report Attribute
Details
Market size in 2023
US$ 44,385.94 Million
Market Size by 2031
US$ 1,68,467.30 Million
Global CAGR (2023 - 2031)
18.1%
Historical Data
2021-2022
Forecast period
2024-2031
Segments Covered
By Product
By Material
By Application
By End User
Regions and Countries Covered
North America
Market leaders and key company profiles
North America Blood Collection Tubes for Liquid Biopsy Regional Insights
The North America blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.
By product, the North America blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the North America blood collection tubes for liquid biopsy market share in 2023.
In terms of material, the North America blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the North America blood collection tubes for liquid biopsy market share in 2023.
By application, the North America blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the North America blood collection tubes for liquid biopsy market share in 2023.
In terms of end user, the North America blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the North America blood collection tubes for liquid biopsy market share in 2023.
Based on country, the North America blood collection tubes for liquid biopsy market is segmented into the US, Canada, and Mexico. The US segment held the largest share of North America blood collection tubes for liquid biopsy market in 2023.
Apostle Sciences; Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the North America blood collection tubes for liquid biopsy market.
The North America Blood Collection Tubes for Liquid Biopsy Market is valued at US$ 44,385.94 Million in 2023, it is projected to reach US$ 1,68,467.30 Million by 2031.
As per our report North America Blood Collection Tubes for Liquid Biopsy Market, the market size is valued at US$ 44,385.94 Million in 2023, projecting it to reach US$ 1,68,467.30 Million by 2031. This translates to a CAGR of approximately 18.1% during the forecast period.
The North America Blood Collection Tubes for Liquid Biopsy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Blood Collection Tubes for Liquid Biopsy Market report:
The North America Blood Collection Tubes for Liquid Biopsy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Blood Collection Tubes for Liquid Biopsy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Blood Collection Tubes for Liquid Biopsy Market value chain can benefit from the information contained in a comprehensive market report.